Advertisement
News
Subscribe to MDT Magazine News

Marinus Pharmaceuticals Issued Patent for Ganaxolone

April 7, 2011 5:35 am | by Bio-Medicine.Org | Comments

NEW HAVEN, Conn., April 7, 2011 /- Marinus Pharmaceuticals, Inc., the leader in development of neurosteroids for central nervous system disorders, today announced that the United States Patent and Trademark Office (USPTO) issued the company Patent Number 7,858,609 entitled, "Solid...

TOPICS:

Shionogi Announces Commercial Availability of CUVPOSAâ„¢ (Glycopyrrolate) Oral Solution for Pediatric Chronic Severe Drooling Associated With Neurologic Conditions

April 7, 2011 5:34 am | by Bio-Medicine.Org | Comments

FLORHAM PARK, N.J., April 7, 2011 /- Shionogi Inc., the U.S.-based group company of Shionogi & Co., Ltd., today announced the U.S. commercial availability of CUVPOSA™ (glycopyrrolate) oral solution, the first and only FDA-approved treatment to reduce chronic severe drooling in...

TOPICS:

NewCardio Study Shows my3KG Improves Diagnostic Accuracy in Diabetics With Acute Myocardial Infarction

April 7, 2011 5:33 am | by Bio-Medicine.Org | Comments

SANTA CLARA, Calif., April 7, 2011 /- PR Newswire – NewCardio, Inc., (OTC BB: NWCI) a cardiac diagnostic technology provider, announced today that the Company has been invited by the American Diabetes Association (ADA) to present the results of a key study showing that NewCardio's...

TOPICS:
Advertisement

Cardinal Health to Release Third Quarter Results on April 28

April 7, 2011 4:37 am | by Bio-Medicine.Org | Comments

DUBLIN, Ohio, April 7, 2011 /- Cardinal Health plans to release third-quarter financial results for its fiscal 2011 on Thursday, April 28, prior to the opening of trading on the New York Stock Exchange. The company has scheduled a webcast and conference call for April 28 at 8:30 a.m. EDT...

TOPICS:

Data from FREEDOM-301 Study for LEVADEXâ„¢ Orally Inhaled Migraine Drug Published in 'Headache'

April 7, 2011 4:36 am | by Bio-Medicine.Org | Comments

MOUNTAIN VIEW, Calif., April 7, 2011 /PRNewswire/ -- MAP Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced the publication of results from the Phase 3 FREEDOM-301 study of  LEVADEX™ orally inhaled migraine drug in the peer-reviewed journal 'Headache.' The manuscript, titled...

TOPICS:

Reportlinker Adds Asia Pacific Markets for Dental Bone Graft Substitutes and Other Biomaterials 2011

April 7, 2011 4:35 am | by Bio-Medicine.Org | Comments

NEW YORK, April 7, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: Asia Pacific Markets for Dental Bone Graft Substitutes and Other Biomaterials 2011...

TOPICS:

Experts issue recommendations for evaluating and treating pituitary incidentalomas

April 7, 2011 4:33 am | by EurekAlert | Comments

(The Endocrine Society) Today, the Endocrine Society released a new Clinical Practice Guideline (CPG) for the evaluation and treatment of pituitary incidentalomas. The CPG is published in the April 2011 issue of the Journal of Clinical Endocrinology & Metabolism, a publication of the...

TOPICS:

Reportlinker Adds European Markets for Interventional Cardiology Devices 2011 (15 Countries)

April 7, 2011 4:33 am | by Bio-Medicine.Org | Comments

NEW YORK, April 7, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: European Markets for Interventional Cardiology Devices 2011 (15 Countries)...

TOPICS:
Advertisement

Reportlinker Adds World In Vitro Diagnostics Market

April 7, 2011 4:33 am | by Bio-Medicine.Org | Comments

NEW YORK, April 7, 2011 /- Reportlinker.com announces that a new market research report is available in its catalogue: World In Vitro Diagnostics Market http://www.reportlinker.com/p0470752/World-In-Vitro-Diagnostics-Market.html Global demand to increase 6.1% annually through 2014 The...

TOPICS:

A Century of Healthcare Innovation from IBM

April 7, 2011 4:32 am | by IBM | Comments

To mark World Health Day, IBM announced several new contributions to public health as well as historical breakthroughs of the past that have contributed to Smarter Healthcare. E-mail this page Save to del.icio.us Digg this

TOPICS:

Bend Research Receives Patent for Technology That Enhances the Bioavailability of Low-Solubility Drugs

April 7, 2011 2:36 am | by Bio-Medicine.Org | Comments

BEND, Ore., April 7, 2011 /- Bend Research Inc. ( www.bendres.com ), a leading independent drug-formulation development and manufacturing company, announced that it has received a new U.S. patent covering the use of polymer additives to improve and sustain the bioavailability of...

TOPICS:

Cellular Dynamics Raises $30 Million to Expand Its Product Line of Human Stem Cells and Tissue Cells

April 7, 2011 2:34 am | by Bio-Medicine.Org | Comments

MADISON, Wis., April 7, 2011 /- Cellular Dynamics International, Inc. (CDI), the world's only industrial manufacturer of human induced pluripotent stem cells (iPSCs) and tissue cells, has closed on a $30 million private equity round. This recent Series B Preferred Stock financing was led...

TOPICS:

New materials based on carbon nanoparticles

April 6, 2011 8:37 pm | by I-Micronews | Comments

Tekniker-IK4 is taking part in a European project investigating new materials based on carbonaceous nanoparticles for application to sectors such as automobiles and construction.

Covidien Receives FDA Premarket Approval for Pipeline(R) Embolization Device(3)

April 6, 2011 4:39 pm | by Covidien | Comments

MANSFIELD, Mass., Apr 06, 2011 (BUSINESS WIRE) --Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Pipeline(R) Embolization Device, indicated for the...

TOPICS:

Covidien Receives FDA Premarket Approval for Pipeline(R) Embolization Device(2)

April 6, 2011 4:37 pm | Comments

MANSFIELD, Mass., Apr 06, 2011 (BUSINESS WIRE) --Covidien (NYSE:COV), a leading global provider of healthcare products, today announced that it received Premarket Approval (PMA) from the U.S. Food and Drug Administration (FDA) for the Pipeline(R) Embolization Device, indicated for the...

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading